Current status and future directions of immunotherapy for advanced non-small cell lung cancer
Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2022-06-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1658380573654-114096025.pdf |
| _version_ | 1828411176571109376 |
|---|---|
| author | SU Chunxia, ZHOU Caicun |
| author_facet | SU Chunxia, ZHOU Caicun |
| author_sort | SU Chunxia, ZHOU Caicun |
| collection | DOAJ |
| description | Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1 (PD-L1) has become one of the standard treatments for advanced NSCLC. This review, with the focus on advanced NSCLC, summarized the development of immunotherapy, discussed current problems, and challenges and proposed future directions. |
| first_indexed | 2024-12-10T12:25:00Z |
| format | Article |
| id | doaj.art-28e34d327e4d4c09a36547e51fb2915a |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-12-10T12:25:00Z |
| publishDate | 2022-06-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-28e34d327e4d4c09a36547e51fb2915a2022-12-22T01:48:58ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392022-06-0132647848610.19401/j.cnki.1007-3639.2022.06.002Current status and future directions of immunotherapy for advanced non-small cell lung cancerSU Chunxia, ZHOU Caicun0Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, ChinaLung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Immune checkpoint inhibitors (ICIs)-based therapy targeting programmed death protein-1 (PD-1) or its ligand programmed death ligand-1 (PD-L1) has become one of the standard treatments for advanced NSCLC. This review, with the focus on advanced NSCLC, summarized the development of immunotherapy, discussed current problems, and challenges and proposed future directions.http://www.china-oncology.com/fileup/1007-3639/PDF/1658380573654-114096025.pdf|non-small cell lung cancer|immune checkpoint inhibitor|immunotherapy |
| spellingShingle | SU Chunxia, ZHOU Caicun Current status and future directions of immunotherapy for advanced non-small cell lung cancer Zhongguo aizheng zazhi |non-small cell lung cancer|immune checkpoint inhibitor|immunotherapy |
| title | Current status and future directions of immunotherapy for advanced non-small cell lung cancer |
| title_full | Current status and future directions of immunotherapy for advanced non-small cell lung cancer |
| title_fullStr | Current status and future directions of immunotherapy for advanced non-small cell lung cancer |
| title_full_unstemmed | Current status and future directions of immunotherapy for advanced non-small cell lung cancer |
| title_short | Current status and future directions of immunotherapy for advanced non-small cell lung cancer |
| title_sort | current status and future directions of immunotherapy for advanced non small cell lung cancer |
| topic | |non-small cell lung cancer|immune checkpoint inhibitor|immunotherapy |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1658380573654-114096025.pdf |
| work_keys_str_mv | AT suchunxiazhoucaicun currentstatusandfuturedirectionsofimmunotherapyforadvancednonsmallcelllungcancer |